You are already at the latest version Background: Relapsed/refractory multiple myeloma (RRMM) is marked by frequent triple-class refractoriness and poor survival, whereas bispecific antibodies targeting BCMA, GPRC5D, or FcRH5 show meaningful activity even in heavily pretreated populations. This meta-analysis evaluates and compares the efficacy and safety of these agents in RRMM. Methods: We searched 7 databases and finalised 44 studies.
T. Amonica
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with T.
Contact T., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack